Aqua Connect, Inc. v. TeamViewer US, Inc.

CourtDistrict Court, D. Delaware
DecidedJanuary 28, 2020
Docket1:18-cv-01572
StatusUnknown

This text of Aqua Connect, Inc. v. TeamViewer US, Inc. (Aqua Connect, Inc. v. TeamViewer US, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aqua Connect, Inc. v. TeamViewer US, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

AQUA CONNECT, INC. and STRATEGIC ) TECHNOLOGY PARTNERS, LLC ) ) Plaintiffs, ) ) v. ) C.A. No. 18-1572 (MN) ) TEAMVIEWER US, LLC, ) ) Defendant. )

MEMORANDUM ORDER

At Wilmington this 28th day of January 2020: IT IS HEREBY ORDERED that the claim term of U.S. Patent Nos. RE46,386 (“the ’386 Patent”) with an agreed-upon construction is construed as follows (see D.I. 96 at 3): 1. “undated” means “updated” Further, as announced at the hearing on January 23, 2020, IT IS HEREBY ORDERED that the disputed claim terms of the ’386 Patent and U.S. Patent No. 8,924,502 (“the ’502 Patent”) are construed as follows: 1. “Mach-derived” means “derived from an operating system kernel developed at Carnegie Mellon University (CMU) from 1985 to 1994” (’386 Patent, claims 1, 8, 10, 21, 22, 25, 27- 29, 31-35; ’502 Patent, claims 1, 8, 21, 25, 27-29, 31-39) 2. “Mach context(s)” means “context(s) running on a Mach-derived operating system” (’386 Patent, claims 1, 8, 10, 21, 22, 25, 27- 29, 31-35; ’502 Patent, claims 1, 8, 21, 25, 27-29, 31-39) The parties briefed the issues (see D.I. 96) and submitted an appendix containing both intrinsic and extrinsic evidence (see D.I. 97; see also D.I. 60, 68 & 104).1 Both sides provided a

1 The Joint Claim Construction Brief contained a number of disputed terms for construction. (See D.I. 86 at ii-iv). After meeting and conferring in an attempt to narrow issues prior to the hearing in response to the Court’s now-standard order (see D.I. 100), the parties reached tutorial describing the relevant technology. (See D.I. 95 & 98). The Court carefully reviewed all submissions in connection with the parties’ contentions regarding the disputed claim terms, heard oral argument (see D.I. 110) and applied the following legal standards in reaching its decision: I. LEGAL STANDARDS

A. Claim Construction “[T]he ultimate question of the proper construction of the patent [is] a question of law,” although subsidiary fact-finding is sometimes necessary. Teva Pharms. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831, 837-38 (2015). “[T]he words of a claim are generally given their ordinary and customary meaning [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc) (internal citations and quotation marks omitted). Although “the claims themselves provide substantial guidance as to the meaning of particular claim terms,” the context of the surrounding words of the claim also must be considered. Id. at 1314. “[T]he ordinary meaning of a claim term is its meaning

to the ordinary artisan after reading the entire patent.” Id. at 1321 (internal quotation marks omitted). The patent specification “is always highly relevant to the claim construction analysis . . . [as] it is the single best guide to the meaning of a disputed term.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). It is also possible that “the specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor’s lexicography governs.” Phillips, 415 F.3d at

agreement that only the “Mach” terms required construction (see D.I. 103; see also D.I. 104). Thus, the other terms that were briefed will have their plain and ordinary meanings. 1316. “Even when the specification describes only a single embodiment, [however,] the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction.” Hill-Rom Servs., Inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (internal quotation marks

omitted) (quoting Liebel-Flarsheim Co. v. Medrad, Inc., 358 F.3d 898, 906 (Fed. Cir. 2004)). In addition to the specification, a court “should also consider the patent’s prosecution history, if it is in evidence.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995) (en banc), aff’d, 517 U.S. 370 (1996). The prosecution history, which is “intrinsic evidence, . . . consists of the complete record of the proceedings before the PTO [Patent and Trademark Office] and includes the prior art cited during the examination of the patent.” Phillips, 415 F.3d at 1317. “[T]he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the course of prosecution, making the claim scope narrower than it would otherwise be.” Id.

In some cases, courts “will need to look beyond the patent’s intrinsic evidence and to consult extrinsic evidence in order to understand, for example, the background science or the meaning of a term in the relevant art during the relevant time period.” Teva, 135 S. Ct. at 841. Extrinsic evidence “consists of all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” Markman, 52 F.3d at 980. Expert testimony can be useful “to ensure that the court’s understanding of the technical aspects of the patent is consistent with that of a person of skill in the art, or to establish that a particular term in the patent or the prior art has a particular meaning in the pertinent field.” Phillips, 415 F.3d at 1318. Nonetheless, courts must not lose sight of the fact that “expert reports and testimony [are] generated at the time of and for the purpose of litigation and thus can suffer from bias that is not present in intrinsic evidence.” Id. Overall, although extrinsic evidence “may be useful to the court,” it is “less reliable” than intrinsic evidence, and its consideration “is unlikely to result in a reliable interpretation of patent claim scope unless considered in the context of the

intrinsic evidence.” Id. at 1318-19. Where the intrinsic record unambiguously describes the scope of the patented invention, reliance on any extrinsic evidence is improper. See Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1308 (Fed. Cir. 1999) (citing Vitronics, 90 F.3d at 1583). B. Indefiniteness Section 112 of the Patent Act requires a patent applicant to “particularly point out and distinctly claim the subject matter” regarded as the applicant’s invention. 35 U.S.C. § 112 ¶ 2. “The primary purpose of the definiteness requirement is to ensure that the claims are written in such a way that they give notice to the public of the extent of the legal protection afforded by the patent, so that interested members of the public, e.g. competitors of the patent owner, can determine whether or not they infringe.” All Dental Prodx, LLC v. Advantage Dental Prods., Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
535 U.S. 722 (Supreme Court, 2002)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
Technology Licensing Corp. v. Videotek, Inc.
545 F.3d 1316 (Federal Circuit, 2008)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Hill-Rom Services, Inc. v. Stryker Corporation
755 F.3d 1367 (Federal Circuit, 2014)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
789 F.3d 1335 (Federal Circuit, 2015)
Ethicon Endo-Surgery, Inc. v. Covidien, Inc.
796 F.3d 1312 (Federal Circuit, 2015)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Aqua Connect, Inc. v. TeamViewer US, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/aqua-connect-inc-v-teamviewer-us-inc-ded-2020.